Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.



Figure 2 Inhibition of receptor-localized phosphoinositide 3-kinase (PI3K) activity does not affect downstream signaling pathways. (a) Northern blotting analysis showing ß-adrenergic receptor (ß1AR) levels in 12-week-old wild type (WT), calsequestrin (CSQ), and CSQ/catalytically inactive PI3K{gamma} (CSQ/PI3K{gamma}inact) hearts (upper panel); equal loading of the different RNA samples was confirmed by methylene blue staining of nylon membranes (bottom panel). (b to e) Mitogen-activated protein kinase activation was determined in WT, CSQ, and CSQ/PI3K{gamma}inact hearts by the ability to in vitro phosphorylate myelin binding protein (MBP) or recombinant glutathione S transferase-proto-oncogene c-Jun (GST-cJun). Representative kinase assays and relative densitometric evaluation of at least six independent experiments are shown for extracellular signal-related kinase (ERK) (b), c-Jun N-terminal kinase (JNK) (c), p38 (d), and p38ß (e). Western blotting was carried out to evaluate total protein levels of each kinase (b to d). *p < 0.01 for CSQ or CSQ/PI3K{gamma}inact versus WT (analysis of variance with Neuman-Keuls correction). (f) Western blotting analysis showing similar activation of protein kinase B (PKB) and glycogen synthase kinase (GSK) under basal conditions in single CSQ and binary CSQ/PI3K{gamma}inact mice. IB = immunoblotting; IP = immunoprecipitation.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement